Skip to main content
Top

01-04-2016 | Colorectal cancer | Article

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

Journal: Clinical and Translational Oncology

Authors: P. García-Alfonso, J. Feliú, R. García-Carbonero, C. Grávalos, C. Guillén-Ponce, J. Sastre, J. García-Foncillas

Publisher: Springer International Publishing

Abstract

Treatment with regorafenib has demonstrated statistically significant improvements in terms of overall survival, progression-free survival and disease control when compared with placebo in pretreated patients with metastatic colorectal cancer in two placebo-controlled, randomized, phase III trials (CORRECT and CONCUR). Similar results were observed in two open-label, single-arm studies (REBECCA and CONSIGN) performed in the real-world setting. But several authors have suggested that the benefit provided by regorafenib may not be clinically meaningful for these patients. Moreover, it has been suggested that not all subgroups of patients might benefit from regorafenib. The intention of this review is to provide an overview of the existing evidence for regorafenib in terms of efficacy, tolerability and quality of life in different subpopulations according to clinical and biological characteristics. Additionally, the magnitude of the clinical benefit provided by regorafenib to these patients has been explored and whether there are poorer outcomes in certain subpopulations.
Literature
1.
WHO, International, Agency, for, Research, on, et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. http://​globocan.​iarc.​fr/​Pages/​fact_​sheets_​population.​aspx. Accessed 30 Sept 2015.
2.
Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134(5):1296–310. doi:10.​1053/​j.​gastro.​2008.​02.​098.CrossRefPubMedPubMedCentral
3.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. doi:10.​1056/​NEJMoa032691.CrossRefPubMed
4.
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–8. doi:10.​1056/​NEJMoa071834.CrossRefPubMed
5.
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706–13. doi:10.​1200/​JCO.​2009.​27.​6055.CrossRefPubMed
6.
Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer. 2013;109(7):1735–43. doi:10.​1038/​bjc.​2013.​523.CrossRefPubMedPubMedCentral
7.
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. doi:10.​1016/​S0140-6736(12)61900-X.CrossRefPubMed
8.
Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–29. doi:10.​1016/​S1470-2045(15)70156-7.CrossRefPubMed
9.
Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–55. doi:10.​1002/​ijc.​25864.CrossRefPubMed
10.
Goldstein DA, Ahmad BB, Chen Q, Ayer T, Howard DH, Lipscomb J, et al. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol. 2015;. doi:10.​1200/​JCO.​2015.​61.​9569.
11.
Tougeron D, Desseigne F, Etienne PL, Dourthe LM, Mineur L, Paule B, et al. REBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC). Ann Oncol. 2014;25(4):iv167–209. doi:10.​1093/​annonc/​mdu333.
12.
Van Cutsem E, Ciardiello F, Seitz J-F, Hofheinz R, Verma U, Garcia-Carbonero R, et al. LBA-05Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol. 2015;26(Suppl 4):iv118. doi:10.​1093/​annonc/​mdv262.​05.CrossRef
13.
de la Fouchardière C, Paule B, Burtin P, Wallet J, Tougeron D, Dourthe LM, et al., editors. Survival benefit, safety, and prognostic factors for outcome with regorafenib (REG) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study. In: European oncology congress, Vienna, Austria; 2015.
14.
Van Cutsem E, Ciardiello F, Seitz JF, Hofheinz RD, Verma U, Garcia-Carbonero R, et al., editors. CONSIGN: an open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy. In: European oncology congress, Vienna, Austria; 2015.
15.
Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547–73. doi:10.​1093/​annonc/​mdv249.CrossRefPubMed
16.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Eng J Med. 2015;372(20):1909–19. doi:10.​1056/​NEJMoa1414325.CrossRef
17.
Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002;7(3):181–7.CrossRefPubMed
18.
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9. doi:10.​1200/​JCO.​2007.​14.​9930.CrossRefPubMed
19.
Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(21):2338–44. doi:10.​1001/​jama.​2009.​1755.CrossRefPubMedPubMedCentral
20.
van Reenen M, Janssen B, Oppe M, Kreimeier S, Greiner W. EQ-5D-Y user guide. Basic information on how to use the EQ-5D-Y instrument. Version 1.0, Rotterdam, The Netherlands; 2014.
21.
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: EORTC; 2001.
22.
Siena S, Grothey A, Sobrero A, Falcone A, Ychou M, Lenz HJ, et al. Effects of regorafenib therapy on health-related quality of life in patients with metastatic colorectal cancer in the phase III CORRECT study. Eur J Cancer. 2013;49(2):Abstract 2156.
23.
Chang J, Pawar V, Grothey A, Sobrero A, Siena S, Falcone A, et al. Time to health status deterioration in regorafenib-treated patients with metastatic colorectal cancer (mCRC): a post hoc analysis of the phase III CORRECT study. Eur J Cancer. 2013;49(2):Abstract 2361.
24.
Chang J, Odom D, Radder C, Kappeler C, Xu R-h, Qin S, et al. A post hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. ASCO Meet Abstr. 2015;33(3_Suppl):667.
25.
Qin S, Kim TW, Yau TC, Ma B, Pan H, Xu J-M, et al. Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. ASCO Meet Abstr. 2015;33(3_Suppl):697.
26.
Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investig New Drugs. 2015;33(3):740–50. doi:10.​1007/​s10637-014-0154-x.CrossRef
27.
van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, et al., editors. Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): analysis of age subgroups in the phase III CORRECT trial. In: ASCO meeting abstracts, 17 June 2013; 2013.
28.
Grothey A, Falcone A, Humblet Y, Bouche O, Mineur L, Adenis A, et al. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months. ASCO Meet Abstr. 2015;33(15_Suppl):e14579.
29.
Rechsteiner M, Wild P, Kiessling MK, Bohnert A, Zhong Q, Stahel RA, et al. A novel germline mutation of PDGFR-beta might be associated with clinical response of colorectal cancer to regorafenib. Ann Oncol. 2015;26(1):246–8. doi:10.​1093/​annonc/​mdu471.CrossRefPubMed
30.
Fan LC, Teng HW, Shiau CW, Lin H, Hung MH, Chen YL, et al. SHP-1 is a target of regorafenib in colorectal cancer. Oncotarget. 2014;5(15):6243–51.CrossRefPubMedPubMedCentral
31.
Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16(8):937–48. doi:10.​1016/​S1470-2045(15)00138-2.CrossRefPubMed